Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Bambino Gesù Hospital and Research Institute
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).
This description comes directly from the study's public registry record.
Franco Locatelli, MD, PhD · +39066859 · franco.locatelli@opbg.net
Francesca del Bufalo, MD, PhD · +39066859 · francesca.delbufalo@opbg.net
Always discuss trial participation with your own doctor first.
| Ospedale Pediatrico Bambino Gesù | Rome, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06080191